CTS Stock Analysis: CTS | NYSE
Electronic Components | NYSE, USA | Market Cap: 1.745m USD | 12M Return: 48.3% | US1265011056 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 14.3M
EPS Trend: 54.5%
Qual. Beats: 2
Rev. Trend: 12.8%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
CTS Corporation is a U.S.-based designer and manufacturer of electronic components, specializing in sensors, connectivity products, and actuators. Its product portfolio spans controls, pedals, switches, transducers, piezo sensing devices, EMI/RFI filters, capacitors, resistors, RF filters, frequency control products, and both piezo microactuators and rotary actuators. The company serves a diversified set of end markets, including transportation, industrial, medical, aerospace, and defense, and distributes its products through a mix of direct sales engineers, independent manufacturer representatives, and third-party distributors. Founded in 1896 and headquartered in Lisle, Illinois, CTS trades on the NYSE under the ticker CTS and is classified within the Information Technology sector under the Electronic Manufacturing Services sub-industry.
Electronic Manufacturing Services (EMS) and component suppliers like CTS typically operate a business model built on long product life cycles, customer-specific design wins, and qualification into regulated or safety-critical applications such as automotive, medical, and aerospace systems. Diversification across multiple end markets is common in this space, helping offset cyclicality in any single industry, while a global manufacturing and sales footprint in North America, Europe, and Asia supports proximity to key OEM customers and supply chain partners.
- EV adoption boosts transportation sensor demand
- Aerospace and defense revenue grows on higher margins
- Acquisitions expand sensor and connectivity product portfolio
| Net Income: 69.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 0.40 > 1.0 |
| NWC/Revenue: 31.27% < 20% (prev 30.95%; Δ 0.31% < -1%) |
| CFO/TA 0.14 > 3% & CFO 109.0m > Net Income 69.8m |
| Net Debt (43.0m) to EBITDA (131.9m): 0.33 < 3 |
| Current Ratio: 2.61 > 1.5 & < 3 |
| Outstanding Shares: last quarter (29.0m) vs 12m ago -3.46% < -2% |
| Gross Margin: 39.33% > 18% (prev 37.82%; Δ 1.51% > 0.5%) |
| Asset Turnover: 71.67% > 50% (prev 66.40%; Δ 5.26% > 0%) |
| Interest Coverage Ratio: 23.04 > 6 (EBIT TTM 96.8m / Interest Expense TTM 4.20m) |
| A: 0.22 (Total Current Assets 286.4m - Total Current Liabilities 109.8m) / Total Assets 791.5m |
| B: 0.94 (Retained Earnings 747.5m / Total Assets 791.5m) |
| C: 0.12 (EBIT TTM 96.8m / Avg Total Assets 788.1m) |
| D: 2.62 (Book Value of Equity 572.8m / Total Liabilities 218.7m) |
| Altman-Z'' = 8.12 = AAA |
| DSRI: 0.96 (Receivables 92.2m/88.2m, Revenue 564.8m/521.1m) |
| GMI: 0.96 (GM 37.82% / 39.33%) |
| AQI: 0.93 (AQ_t 0.49 / AQ_t-1 0.52) |
| SGI: 1.08 (Revenue 564.8m / 521.1m) |
| TATA: -0.05 (NI 69.8m - CFO 109.0m) / TA 791.5m) |
| Beneish M = -3.07 (Cap -4..+1) = AA |
As of October 09, 2026, the stock is trading at USD 57.31 with a total of 211,037 shares traded. Over the past week, the price has changed by -4.18%, over one month by +1.09%, over three months by -2.90% and over the past year by +48.26%.
Current recommended Stop Loss: 54.90 (which is 4.2% or 1.3 ATR below the current price).
CTS has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy CTS.
- StrongBuy: 1
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 70.7 | 23.3% |
P/E Trailing = 25.7806
P/E Forward = 19.8413
P/S = 3.0922
P/B = 2.8685
P/EG = 1.2401
Revenue TTM = 564.8m USD
EBIT TTM = 96.8m USD
EBITDA TTM = 131.9m USD
Long Term Debt = 55.0m USD (from longTermDebt, last quarter)
Short Term Debt = 19.3m USD (from shortTermDebt, last quarter)
Debt = 150.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 34.9m
Net Debt = 43.0m USD (calculated: Debt 150.6m - CCE 107.5m)
Enterprise Value = 1.79b USD (1.74b + Debt 150.6m - CCE 107.5m)
Interest Coverage Ratio = 23.04 (Ebit TTM 96.8m / Interest Expense TTM 4.20m)
EV/FCF = 19.56x (Enterprise Value 1.79b / FCF TTM 91.4m)
FCF Yield = 5.11% (FCF TTM 91.4m / Enterprise Value 1.79b)
FCF Margin = 16.18% (FCF TTM 91.4m / Revenue TTM 564.8m)
Net Margin = 12.36% (Net Income TTM 69.8m / Revenue TTM 564.8m)
Gross Margin = 39.33% ((Revenue TTM 564.8m - Cost of Revenue TTM 342.7m) / Revenue TTM)
Gross Margin QoQ = 41.49% (prev 38.45%)
Tobins Q-Ratio = 2.26 (Enterprise Value 1.79b / Total Assets 791.5m)
Interest Expense / Debt = 2.79% (Interest Expense 4.20m / Debt 150.6m)
Taxrate = 24.62% (22.8m / 92.6m)
NOPAT = 73.0m (EBIT 96.8m * (1 - 24.62%))
Current Ratio = 2.61 (Total Current Assets 286.4m / Total Current Liabilities 109.8m)
Debt / Equity = 0.26 (Debt 150.6m / totalStockholderEquity, last quarter 572.8m)
Debt / EBITDA = 0.33 (Net Debt 43.0m / EBITDA 131.9m)
Debt / FCF = 0.47 (Net Debt 43.0m / FCF TTM 91.4m)
Total Stockholder Equity = 557.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.85% (Net Income 69.8m / Total Assets 791.5m)
RoE = 12.52% (Net Income TTM 69.8m / Total Stockholder Equity 557.4m)
RoCE = 15.80% (EBIT 96.8m / Capital Employed (Equity 557.4m + L.T.Debt 55.0m))
RoIC = 10.84% (NOPAT 73.0m / Invested Capital 672.8m)
WACC = 9.63% (E(1.74b)/V(1.90b) * Re(10.28%) + D(150.6m)/V(1.90b) * Rd(2.79%) * (1-Tc(0.25)))
Discount Rate = 10.28% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -97.59 | Cagr: -2.99%
[DCF] Terminal Value 71.72% ; FCFF base≈89.8m ; Y1≈93.6m ; Y5≈106.6m
[DCF] Fair Price = 45.73 (EV 1.35b - Net Debt 43.0m = Equity 1.31b / Shares 28.6m; r=9.63% [WACC]; 5y FCF grow 4.46% → 2.50% )
EPS Correlation: 54.46 | EPS CAGR: 4.17% | SUE: 2.56 | # QB: 2
Revenue Correlation: 12.83 | Revenue CAGR: 0.54% | SUE: 0.27 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.65 | Chg30d=-3.93% | Revisions=-25% | Analysts=3
EPS current Year (2026-12-31): EPS=2.65 | Chg30d=-2.45% | Revisions=-25% | GrowthEPS=+19.0% | GrowthRev=+5.9%
EPS next Year (2027-12-31): EPS=2.87 | Chg30d=-3.80% | Revisions=-25% | GrowthEPS=+8.0% | GrowthRev=+6.1%
[Analyst] Revisions Ratio: -50% (up=0, down=3)